Chirag P. Shah
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chirag P. Shah has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Jeffrey S. Heier
5 shared publications- Adam Rogers
Vitreoretinal Service, Departments of Ophthalmology, New England Eye Center, Tufts University School of Medicine, 260 Tremont Street, Boston, MA 02116 USA
1 shared publication - Andre J. Witkin
New England Eye Center, Tufts Medical Center, 800 Washington Street, Box 450, Boston, MA 02111 USA
1 shared publication Boston Ophthalmic Consultants Of Boston
1 shared publication- Caroline R. Baumal
Apellis Pharmaceuticals, Waltham, Massachusetts, USA
1 shared publication Carolyn Chen
Ophthalmic Consultants of Boston and Department of Ophthalmology, Tufts-New England Eye Center, Boston, MA, USA
1 shared publication
Latest Publications
- Open Access
- 1 January 2023
- Published by Touch Medical Media, Ltd. in US Ophthalmic Review
- Vol. 17 (1)
Submacular Choroidal Granuloma from Sarcoidosis: A Case Report
Introduction: This article reports two cases of submacular choroidal granuloma from sarcoidosis, highlighting the critical importance of timely diagnosis and treatment for both visual and systemic prognosis. Case studies: Case 1 is a 60-year-old man who presented with blurred vision from a submacular choroidal granuloma. Initially, the lesion responded to oral prednisone, however, there was progression once the prednisone was stopped. One year later, he developed complete heart block and was diagnosed with cardiac sarcoidosis. He underwent pacemaker implantation and has been maintained on mycophenolate. Case 2 is a 35-year-old man who presented with distortion from a submacular choroidal granuloma that similarly responded to oral prednisone but progressed after it was discontinued. He had a chest computerized tomography scan and a subsequent lymph node biopsy that confirmed the diagnosis of sarcoidosis. He has remained stable and healthy, with 20/20 vision on methotrexate. Conclusion: Submacular choroidal granuloma from sarcoidosis is a rare condition that can cause vision loss if not treated promptly. These lesions usually respond to local or systemic corticosteroids. Diagnosis of these lesions is critical not only for visual preservation but also to prevent systemic complications.
- 1 January 2023
- Published by Touch Medical Media, Ltd. in US Ophthalmic Review
- Vol. 17 (1)
Open AccessSubmacular Choroidal Granuloma from Sarcoidosis: A Case Report
Introduction: This article reports two cases of submacular choroidal granuloma from sarcoidosis, highlighting the critical importance of timely diagnosis and treatment for both visual and systemic prognosis. Case studies: Case 1 is a 60-year-old man who presented with blurred vision from a submacular choroidal granuloma. Initially, the lesion responded to oral prednisone, however, there was progression once the prednisone was stopped. One year later, he developed complete heart block and was diagnosed with cardiac sarcoidosis. He underwent pacemaker implantation and has been maintained on mycophenolate. Case 2 is a 35-year-old man who presented with distortion from a submacular choroidal granuloma that similarly responded to oral prednisone but progressed after it was discontinued. He had a chest computerized tomography scan and a subsequent lymph node biopsy that confirmed the diagnosis of sarcoidosis. He has remained stable and healthy, with 20/20 vision on methotrexate. Conclusion: Submacular choroidal granuloma from sarcoidosis is a rare condition that can cause vision loss if not treated promptly. These lesions usually respond to local or systemic corticosteroids. Diagnosis of these lesions is critical not only for visual preservation but also to prevent systemic complications.
- 12 July 2022
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 33 (5) , 362-367
How private equity achieves return on investment in ophthalmology
Purpose of review: To review how private equity entities generate profit for investors and ophthalmologists. Recent findings: There is a preponderance of private equity acquisitions and consolidation in ophthalmology. These private equity entities generate revenue by growth, profit improvement, and efficient use of capital structure. Physician partners sell their revenue and assets to a private equity entity while retaining a percentage of future profit. In general, a greater percentage going forward, will result in a smaller initial buyout. Partners typically receive payment in the form of cash and stock in the private equity entity, aligning incentives of both parties to grow and succeed. Junior associates and future partners typically do not benefit from the cash buyout but might have opportunity to buy shares in the private equity entity. Summary: The ophthalmology job market has changed significantly with the rise in private equity. Private equity investors profit from organic growth, economies of scale, and future revenue of ophthalmology practices. Ophthalmology partners benefit from often sizeable buyouts and potentially profitable shares in the private equity entity. Junior and future ophthalmologist may be less likely to succeed financially compared with their contemporaries. Some private equity entities will thrive and other may fail, particularly if they are unable to attract talented new ophthalmologists.
- 12 July 2022
- Published by Wolters Kluwer Health in Current Opinion in Ophthalmology
- Vol. 33 (5) , 362-367
How private equity achieves return on investment in ophthalmology
Purpose of review: To review how private equity entities generate profit for investors and ophthalmologists. Recent findings: There is a preponderance of private equity acquisitions and consolidation in ophthalmology. These private equity entities generate revenue by growth, profit improvement, and efficient use of capital structure. Physician partners sell their revenue and assets to a private equity entity while retaining a percentage of future profit. In general, a greater percentage going forward, will result in a smaller initial buyout. Partners typically receive payment in the form of cash and stock in the private equity entity, aligning incentives of both parties to grow and succeed. Junior associates and future partners typically do not benefit from the cash buyout but might have opportunity to buy shares in the private equity entity. Summary: The ophthalmology job market has changed significantly with the rise in private equity. Private equity investors profit from organic growth, economies of scale, and future revenue of ophthalmology practices. Ophthalmology partners benefit from often sizeable buyouts and potentially profitable shares in the private equity entity. Junior and future ophthalmologist may be less likely to succeed financially compared with their contemporaries. Some private equity entities will thrive and other may fail, particularly if they are unable to attract talented new ophthalmologists.
- 1 February 2020
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 51 (2) , 85-88
Long-Term Follow-Up of Efficacy and Safety of YAG Vitreolysis for Symptomatic Weiss Ring Floaters
BACKGROUND AND OBJECTIVE: To describe long-term outcomes and complications after YAG vitreolysis. PATIENTS AND METHODS: This is an observational extension study to a previously reported, randomized, controlled study. Thirty-five of 52 patients returned at an average of 2.3 years (range: 1.1 to 3.0) after their last YAG vitreolysis treatment to assess long-term efficacy and safety. RESULTS: At 2.3 years, 50% of patients felt their symptoms were significantly or completely better, similar to results at 6 months (53%). There was a 59.4% improvement in symptoms, similar to 6 months (54%). The 25-item National Eye Institute Visual Function Questionnaire revealed improvements in: near activities, distance vision, mental health, and role difficulties. Adverse events included three eyes with delayed retinal tears, noted 1.4 to 2.8 years after YAG vitreolysis. CONCLUSIONS: The efficacy of YAG vitreolysis observed at 6 months was sustained at 2.3 years, with half reporting significant or complete resolution of their floater symptoms. Three patients developed delayed retinal tears not evident at 6 months. A large, long-term randomized controlled trial is needed to determine the true risks of YAG vitreolysis. [ Ophthalmic Surg Lasers Imaging Retina . 2020;51:85–88.]
- 1 February 2020
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 51 (2) , 85-88
Long-Term Follow-Up of Efficacy and Safety of YAG Vitreolysis for Symptomatic Weiss Ring Floaters
BACKGROUND AND OBJECTIVE: To describe long-term outcomes and complications after YAG vitreolysis. PATIENTS AND METHODS: This is an observational extension study to a previously reported, randomized, controlled study. Thirty-five of 52 patients returned at an average of 2.3 years (range: 1.1 to 3.0) after their last YAG vitreolysis treatment to assess long-term efficacy and safety. RESULTS: At 2.3 years, 50% of patients felt their symptoms were significantly or completely better, similar to results at 6 months (53%). There was a 59.4% improvement in symptoms, similar to 6 months (54%). The 25-item National Eye Institute Visual Function Questionnaire revealed improvements in: near activities, distance vision, mental health, and role difficulties. Adverse events included three eyes with delayed retinal tears, noted 1.4 to 2.8 years after YAG vitreolysis. CONCLUSIONS: The efficacy of YAG vitreolysis observed at 6 months was sustained at 2.3 years, with half reporting significant or complete resolution of their floater symptoms. Three patients developed delayed retinal tears not evident at 6 months. A large, long-term randomized controlled trial is needed to determine the true risks of YAG vitreolysis. [ Ophthalmic Surg Lasers Imaging Retina . 2020;51:85–88.]
- 1 June 2018
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 49 (6) , 388-391
Management of Floaters
Ophthalmic Surgery, Lasers and Imaging Retina | Howard F. Fine, Practical Retina Co-Editor Patients with vitreous floaters can be quite symptomatic, leading to psychological distress and even depression. In this installment of Practical Retina, Chirag P. Shah, MD, MPH, from Ophthalmic Consultants of Boston, gives an update on the management of symptomatic vitreous floaters. He highlights a framework for deciding between
- 1 June 2018
- Published by SLACK, Inc. in Ophthalmic Surgery, Lasers and Imaging Retina
- Vol. 49 (6) , 388-391
Management of Floaters
Ophthalmic Surgery, Lasers and Imaging Retina | Howard F. Fine, Practical Retina Co-Editor Patients with vitreous floaters can be quite symptomatic, leading to psychological distress and even depression. In this installment of Practical Retina, Chirag P. Shah, MD, MPH, from Ophthalmic Consultants of Boston, gives an update on the management of symptomatic vitreous floaters. He highlights a framework for deciding between
- 1 April 2018
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 136 (4) , 449-450
Methodological and Efficacy Issues in a Randomized Clinical Trial Investigating Vitreous Floater Treatment—Reply
In Reply We performed this YAG vitreolysis pilot study1 to determine whether the procedure had any value in helping patients with Weiss ring floaters and if there were any obvious adverse effects. We hope the results inspire larger studies of longer duration to better understand YAG vitreolysis on a variety of floater types. YAG vitreolysis works through 3 mechanisms: (1) plasma formation at higher energy levels, visualized as small gas bubbles; (2) the mechanical disruption of vitreous tissue; and (3) the severing of vitreous strands, which allows suspended floaters to drift away from the central visual axis. The balance between plasma formation, disruption, and severing depends on the power of the treatment, floater characteristics, and surgeon technique. Even with plasma formation and vaporization of vitreous tissue, the visual axis cannot be cleared as well with YAG vitreolysis as with vitrectomy. A comparison between YAG vitreolysis and pars plana vitrectomy would be very interesting in helping the ophthalmology community determine the differences in efficacy and safety between these 2 potential treatment options for floaters. However, such a comparison was beyond the scope of our study.
- 1 April 2018
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 136 (4) , 449-450
Methodological and Efficacy Issues in a Randomized Clinical Trial Investigating Vitreous Floater Treatment—Reply
In Reply We performed this YAG vitreolysis pilot study1 to determine whether the procedure had any value in helping patients with Weiss ring floaters and if there were any obvious adverse effects. We hope the results inspire larger studies of longer duration to better understand YAG vitreolysis on a variety of floater types. YAG vitreolysis works through 3 mechanisms: (1) plasma formation at higher energy levels, visualized as small gas bubbles; (2) the mechanical disruption of vitreous tissue; and (3) the severing of vitreous strands, which allows suspended floaters to drift away from the central visual axis. The balance between plasma formation, disruption, and severing depends on the power of the treatment, floater characteristics, and surgeon technique. Even with plasma formation and vaporization of vitreous tissue, the visual axis cannot be cleared as well with YAG vitreolysis as with vitrectomy. A comparison between YAG vitreolysis and pars plana vitrectomy would be very interesting in helping the ophthalmology community determine the differences in efficacy and safety between these 2 potential treatment options for floaters. However, such a comparison was beyond the scope of our study.
- Open Access
- 1 September 2017
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 135 (9) , 918-923
YAG Laser Vitreolysis vs Sham YAG Vitreolysis for Symptomatic Vitreous Floaters
Floaters become more prevalent with age because of degenerative vitreous changes that occur throughout life. In youth, hyaluronan keeps collagen fibrils separated in the vitreous cavity and thus maintains transparency of the vitreous. However, with time, hyaluronan dissociates from collagen, causing cross-linking and aggregation of collagen with fibrous structures that scatter light—a process known as vitreous liquefaction.1-3
- 1 September 2017
- Published by American Medical Association (AMA) in JAMA Ophthalmology
- Vol. 135 (9) , 918-923
Open AccessYAG Laser Vitreolysis vs Sham YAG Vitreolysis for Symptomatic Vitreous Floaters
Floaters become more prevalent with age because of degenerative vitreous changes that occur throughout life. In youth, hyaluronan keeps collagen fibrils separated in the vitreous cavity and thus maintains transparency of the vitreous. However, with time, hyaluronan dissociates from collagen, causing cross-linking and aggregation of collagen with fibrous structures that scatter light—a process known as vitreous liquefaction.1-3
- Open Access
- 18 July 2016
- Published by Springer Nature in International Journal of Retina and Vitreous
- Vol. 2 (1) , 1-11
Expanded spectral domain-OCT findings in the early detection of hydroxychloroquine retinopathy and changes following drug cessation
To report expanded SD-OCT findings of HCQ retinopathy that may assist the clinician in earlier diagnosis. To characterize structural changes of HCQ retinopathy with SD-OCT after drug cessation. Setting: Private practice and academic institution. Patient Population: Patients at New England Eye Center and Ophthalmic Consultants of Boston in Boston, MA diagnosed with HCQ retinopathy and followed after drug cessation. Retrospective clinical data review by the Boston Image Reading Center. Main Outcome Measures: SD-OCT findings suggestive of HCQ retinopathy before parafoveal ellipsoid disruption. Change in SD-OCT morphological appearance and retinal thickness of each of the nine subfields corresponding to the Early Treatment of Diabetic Retinopathy Study areas. Thirty eyes with HCQ retinopathy were followed with SD-OCT after drug cessation. Findings before disruption of the parafoveal EZ included parafoveal outer nuclear layer (ONL) thinning, disruption of the parafoveal interdigitation zone, and reduced reflectivity of the parafoveal EZ. In early toxicity, 75 % developed progression after drug cessation, including disruption of the parafoveal EZ and retinal pigment epithelium and thinning of the ONL. Eyes with obvious toxicity had greater inferior outer ring thinning 12 months after drug cessation compared to early toxicity (p = 0.002, 95 % CI −2 to −8 μm). In obvious toxicity, the nasal inner subfield showed more thinning than the temporal inner subfield at 12 months after drug cessation (p = 0.018, 95 % CI −1 to −8 μm). Once HCQ retinopathy is diagnosed and the medication is discontinued, structural retinal changes commonly occur.
- 18 July 2016
- Published by Springer Nature in International Journal of Retina and Vitreous
- Vol. 2 (1) , 1-11
Open AccessExpanded spectral domain-OCT findings in the early detection of hydroxychloroquine retinopathy and changes following drug cessation
To report expanded SD-OCT findings of HCQ retinopathy that may assist the clinician in earlier diagnosis. To characterize structural changes of HCQ retinopathy with SD-OCT after drug cessation. Setting: Private practice and academic institution. Patient Population: Patients at New England Eye Center and Ophthalmic Consultants of Boston in Boston, MA diagnosed with HCQ retinopathy and followed after drug cessation. Retrospective clinical data review by the Boston Image Reading Center. Main Outcome Measures: SD-OCT findings suggestive of HCQ retinopathy before parafoveal ellipsoid disruption. Change in SD-OCT morphological appearance and retinal thickness of each of the nine subfields corresponding to the Early Treatment of Diabetic Retinopathy Study areas. Thirty eyes with HCQ retinopathy were followed with SD-OCT after drug cessation. Findings before disruption of the parafoveal EZ included parafoveal outer nuclear layer (ONL) thinning, disruption of the parafoveal interdigitation zone, and reduced reflectivity of the parafoveal EZ. In early toxicity, 75 % developed progression after drug cessation, including disruption of the parafoveal EZ and retinal pigment epithelium and thinning of the ONL. Eyes with obvious toxicity had greater inferior outer ring thinning 12 months after drug cessation compared to early toxicity (p = 0.002, 95 % CI −2 to −8 μm). In obvious toxicity, the nasal inner subfield showed more thinning than the temporal inner subfield at 12 months after drug cessation (p = 0.018, 95 % CI −1 to −8 μm). Once HCQ retinopathy is diagnosed and the medication is discontinued, structural retinal changes commonly occur.
- 1 May 2016
- Published by Elsevier in Ophthalmology
- Vol. 123 (5) , 1137-1142
Outcomes after Failed Pneumatic Retinopexy for Retinal Detachment
- 1 May 2016
- Published by Elsevier in Ophthalmology
- Vol. 123 (5) , 1137-1142
Outcomes after Failed Pneumatic Retinopexy for Retinal Detachment
- Open Access
- 1 July 2014
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 8, 1291-3
Treatment of dystrophic calcification on a silicone intraocular lens with pars plana vitrectomy
Purpose: Dense, vision-obscuring calcification on the posterior aspect of silicone intraocular lenses (IOLs) is often not amenable to neodymium:yttrium-aluminum-garnet capsulotomy, and, in prior reports, has required IOL exchange. We report the successful removal of dense calcium deposition on the posterior surface of a three-piece silicone lens using pars plana vitrectomy (PPV). Materials and methods: A 23-gauge PPV was performed using the Stellaris® vitrectomy system. A light pipe was used to retroilluminate the IOL, and a dense fibrous tissue setting with a low cut-rate and high aspiration rate was able to clear the visual axis of the dystrophic calcification without damaging the IOL optic. Results: Visual acuity improved from 20/100 to 20/25. Conclusion: Small-gauge PPV may be utilized to remove dense dystrophic calcium deposits on the lens surface in lieu of IOL exchange.
- 1 July 2014
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 8, 1291-3
Open AccessTreatment of dystrophic calcification on a silicone intraocular lens with pars plana vitrectomy
Purpose: Dense, vision-obscuring calcification on the posterior aspect of silicone intraocular lenses (IOLs) is often not amenable to neodymium:yttrium-aluminum-garnet capsulotomy, and, in prior reports, has required IOL exchange. We report the successful removal of dense calcium deposition on the posterior surface of a three-piece silicone lens using pars plana vitrectomy (PPV). Materials and methods: A 23-gauge PPV was performed using the Stellaris® vitrectomy system. A light pipe was used to retroilluminate the IOL, and a dense fibrous tissue setting with a low cut-rate and high aspiration rate was able to clear the visual axis of the dystrophic calcification without damaging the IOL optic. Results: Visual acuity improved from 20/100 to 20/25. Conclusion: Small-gauge PPV may be utilized to remove dense dystrophic calcium deposits on the lens surface in lieu of IOL exchange.
- 1 July 2011
- Published by Springer Nature
- p. 135-153
The Future of Neovascular Age-Related Macular Degeneration
- 1 July 2011
- Published by Springer Nature
- p. 135-153
The Future of Neovascular Age-Related Macular Degeneration